Related Experiment Video
Updated: Jun 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Demyelinating events in rheumatoid arthritis after drug exposures
Sasha Bernatsky1, Christel Renoux, Samy Suissa
1Centre for Clinical Epidemiology, Jewish General Hospital-Lady Davis Institute, 3755 Cote Ste-Catherine, Montreal, Quebec, Canada.
Objective:
To estimate the effects of biological drugs on the risk of demyelinating events in rheumatoid arthritis (RA).
Methods:
Case-control analyses nested in an administrative database cohort.
Results:
Initially the risk of demyelinating events appeared to be increased after exposure to anakinra and decreased after exposure to antitumour necrosis factor (anti-TNF) agents. However, this apparent differential risk was due to more anakinra use (and avoidance of anti-TNF agents) in persons at high risk for demyelinating events. In individuals not at high risk, the adjusted rate ratio was 1.31 (95% CI 0.68 to 2.50) after exposure to anti-TNF agents and 0.80 (95% CI 0.29 to 2.24) after exposure to anakinra.
Conclusions:
When accounting for differential prescription patterns, there was a trend towards more events after exposure to anti-TNF agents. When studying rare but important potential drug associations, pharmacoepidemiological studies are valuable but must be carefully performed.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Drug toxicity: Idiosyncratic Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Rheumatic Heart Disease I: Introduction
Hypersensitivity Reactions: Immune-Complex Reactions

